Literature DB >> 3158107

The differential inhibitory effects exerted by cyclosporine and hydrocortisone on the activation of human cytotoxic lymphocytes by recombinant interleukin-2 versus allospecific CTL.

E A Grimm, L M Muul, D J Wilson.   

Abstract

Two immunosuppressive drugs, cyclosporine (CsA) and Hydrocortisone (Hy) were examined in parallel for their effect on the generation of cytolytic T lymphocytes (CTL). Peripheral blood lymphocytes (PBL) were stimulated with allogeneic cells to produce allospecific CTL, or with purified recombinant Interleukin 2 to activate lymphokine activated killer cells (LAK). CTL and LAK activity were measured in a 4 hr chromium release assay after 7 days of activation. Lysis by CTL was tested against stimulator PBL (not blasts) and LAK against fresh sarcoma tumor cells. At pharmacologic doses, CsA inhibited only CTL generation, and Hy inhibited only LAK. This greater understanding of the selective role, or roles, in vitro of CsA and Hy provides a basis by which to consider selective immune suppression--and, alternatively, the possibility of combining modalities for a more thorough immune suppression.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3158107     DOI: 10.1097/00007890-198505000-00016

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors.

Authors:  S K Sankhla; J S Nadkarni; S N Bhagwati
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

Review 2.  Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations.

Authors:  R E Merchant; M D Ellison; H F Young
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

3.  BCG induced killer cell activity.

Authors:  S Koga; T Kiyohara; K Taniguchi; M Nishikido; S Kubota; T Sakuragi; K Shindo; Y Saitoh
Journal:  Urol Res       Date:  1988

4.  TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.

Authors:  E A Grimm; W L Crump; A Durett; J P Hester; S Lagoo-Deenadalayan; L B Owen-Schaub
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro.

Authors:  D W McVicar; R E Merchant; L H Merchant; H F Young
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.